Mirica® - Advanced, Enhanced Absorption Formula, Palmitoylethanolamide (PEA) and Luteolin - 60 Capsules
Save Liquid error (product-badge line 32): -Infinity%
Synergistic Combination of Palmitoylethanolamide (PEA) and Luteolin
Mirica® Advanced contains Levagen®+ PEA with Nearly Twice the Absorption of Standard PEA**
Safe, Effective, Non-Addictive Pain Reducer*
Over 800 published studies and Over 50 Clinical Trials support PEA’s anti-inflammatory, neuroprotective, immune supporting, analgesic properties*
Recommended by Doctors*
Increases Your Body’s Natural Pain Reducing Endocannabinoids*
All Young Nutraceuticals Products are manufactured in the USA under strict Good Manufacturing Practices (cGMP) set by the FDA and are produced with the highest quality ingredients and tested by 3rd party lab for purity and potency*
No artificial ingredients
Mirica® Advanced is made from the highest quality pharmaceutical-grade ingredients available. Mirica® Advanced is made with pure Levagen®+ PEA, clinically shown to have nearly twice the absorption of standard PEA. We believe purity matters, especially when a supplement is a daily part of your life. That's why we never compromise on our ingredients.
What is PEA?
Palmitoylethanolamide (PEA) is a biologically active, endogenous lipid that is widely distributed throughout the body's tissues and is synthesized on demand. (Gabrielsson 2016) It was first isolated in 1957 as an anti-inflammatory component in egg yolks and is found in many foods. PEA has been studied extensively for its anti-inflammatory, neuroprotective and analgesic properties since the 1970's.* (Hesselink 2013)
PEA plays a key role in maintaining homeostasis by regulating many physiological reactions associated with pain and inflammation. Some chronic conditions can deplete PEA, resulting in a hyper-immune response involving glial, microglial and mast cells. Excessive activation of these satellite, non-neuronal cells has been shown to maintain inflammation and result in neurodegeneration. PEA reduces excessive activation of these cells and decreases neuron loss.* (Raso 2014)
In a recent meta-analysis of PEA involving a total of 1484 chronic pain patients, those taking PEA reported pain levels an average of 2.7 points lower than the control groups after 60 days.* (Paladini 2016)